Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-04-14
2008-11-04
McKane, Joseph (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S426000, C514S428000, C548S537000, C548S567000, C548S570000
Reexamination Certificate
active
07446125
ABSTRACT:
This invention relates to nitroproline derivative compounds and procedures for their preparation and the preparation of pharmaceutical compositions containing the compounds. The invention also relates to the administration of compounds of the invention as agents for the treatment of mammalian diseases whose pathogenic and pathophysiological mechanisms depend on or are significantly contributed by undesirable cellular and molecular activities or responses induced by integrin-dependent molecular interactions.
REFERENCES:
Zubia et al, published online Apr. 13, 2005, Agnew. Chem. Int. Ed., 44(19), p. 2903-2907.
Wikipedia encyclopedia, VLA-4.
Wikipedia encyclopedia, Cancer.
Annunziata et al., “1,3-Dipolar Cycloaddition Reactions of Azomethine Ylides on Enantiomerically Pure(E)-γ-Alkoxy-α,β-Unsaturated Esters,” Tetrahedron Asymmetry, vol. 2 Issue 12, 1991, 1329-1342.
Galley et al., “Polyfunctionalized Pyrrolidines by Stereoselective 1,3-Dipolar Cycloaddition of Azomethine Ylides to Chiral Enones” 1995 American Chemical Society, J. Org. Chem. 1995, 60 p. 5005-5010.
Barr et al., “X=Y-ZH Compounds as Potential 1,3-Dipoles. Part 431Metal Ion Catalysed Asymmetric 1,3-Dipolar Cycloaddition Reactions of Imines and Menthyl Acrylate,” Tetrahedron vol. 51, No. 1, pp. 273-294, 1995.
Waldmann et al., “Asymmetric Control of 1,3-Dipolar Cycloaddition Reactions with Azomethine Ylides by Means of Proline Esters as Chiral Auxiliary Groups,” Chem. Eur. J. 1995, 1:150-154.
Ayerbe et al., “Stereocontrolled Synthesis of Highly Substituted Proline Esters via [3+2] Cycloaddition between N-Metalated Azomethine Ylides and Nitroalkenes. Origins of the Metal Effect on the Stereochemical Outcome,” J. Org. Chem. 1998, 63, 1795-1805.
Qian et al., “Expression of the Integrin α4β1 on Melanoma Cells Can Inhibit the Invasive Stage of Metastasis Formation,” Cell Press, May 6, 1994, 77:335-347.
Matsuura, et al., “Induction of Experimental Bone Metastasis in Mice by Transfection of Integrin α4β1 into Tumor Cells,” American Journal of Pathology, Jan. 1996, 148:55-61.
Okada et al., “Significance of VLA-4-VCAM-1 interaction and CD44 for transendothelial invasion in a bone marrow metastatic myeloma model,” Clin. Exp. Metastasis 1999; 17:623-629.
Papadimitriou et al., “Integrin α4β1/VCAM-1 pathway mediates primary adhesion of RAW117 lymphoma cells to hepatic sinusoidal endothelial cells under flow,” Clin. Exp. Metastasis 1999; 17:669-676.
Vidal-Vanaclocha et al., Interleukin-1 Receptor Blockade Reduces the Number and Size of Murine B16 Melanoma Hepatic Metastases1, Cancer Research 54, 2667-2672, May 15, 1994.
Anasagasti et al., “Sinusoidal Endothelium Release of Hydrogen Peroxide Enhances Very Late Antigen-4-Mediated Melanoma Cell Adherence and Tumor Cytotoxicity During Interleukin-1 Promotion of Hepatic Melanoma Metastasis in Mice,” Hepatology, Apr. 1997, 25:840-846.
Mendoza et al., “Hydrogen Peroxide Mediates Vascular Cell Adhesion Molecule-1 Expression From Interleukin-18-Activated Hepatic Sinusoidal Endothelium: Implications for Circulating Cancer Cell Arrest in the Murine Liver,” Hepatology, Aug. 2001, 34:298-310.
Vidal-Vanaclocha et al., “IL-18 regulates IL-1β-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1,” PNAS, Jan. 18, 2000, 97:734-739.
Wattanasin et al., “Design and Synthesis of Potent and Selective Inhibitors of Integrin VLA-4,” Bioorganic & Medicinal Chemistry Letters 11 (2001) 2955-2958.
Kopka et al., “Substituted N-(3,5-Dichlorobenzenesulfonyl)-L-prolyl-phenylalanine Analogues as Potent VLA-4 Antagonists,” Bioorganic & Medicinal Chemistry Letters 12 (2002) 637-640.
Chen et al., “N-Acyl-L-phenylalanine Derivatives as Potent VLA-4 Antagonists that Mimic a Cyclic Peptide Conformation,” Bioorganic & Medicinal Chemistry Letters 12 (2002) 137-140.
Lin et al., “Specific and Dual Antagonists of α4β1and α4β7Integrins,” Bioorganic & Medicinal Chemistry Letters 12 (2202) 133-136.
de Groot et al., “Design, Synthesis, and Biological Evaluation of a Dual Tumor-specific Motive Containing Integrin-targeted Plasmin-cleavable Doxorubicin Prodrug1,” Molecular Cancer Therapeutics; Sep. 2002, 1:901-911.
Azuma et al., “Marked Prevention of Tumor Growth and Metastasis by a Novel Immunosuppressive Agent, FTY720, in Mouse Breast Cancer Models,” Cancer Res., Mar. 1, 2002, 62:1410-1418.
Aldaba Arévalo Eneko
Mendoza Arteche Miren Lorea
Pedro Cossio Fernando
Valcárcel Cuesta María
Vara Salazr Yosu Ion
Chu Yong
Darby & Darby
Dominion Pharmakine S.L.
McKane Joseph
Universidad del Pais Vasco
LandOfFree
Derivatives of nitroproline compounds, processes of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Derivatives of nitroproline compounds, processes of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Derivatives of nitroproline compounds, processes of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4032546